Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system

Shuraila F. Zerp(The Netherlands Cancer Institute), Marcel Verheij(The Netherlands Cancer Institute)

Clinical and Translational Radiation Oncology

June 9, 2020

10.1016/j.ctro.2020.05.012

Cited by 9

Related Papers

AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis

|Radiation Oncology|2009|58

Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer

|Radiation Oncology|2015|49

Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency

|Biochemical Journal|2009|19